Oncology and Hematology

Episodes 81-96 of 386

The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Project Oncology®
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
- Charles Turck, PharmD, BCPS, BCCCP
- Thomas Egenod, MD
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Project Oncology®
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
- Ben Park, MD, PhD
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Project Oncology®
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
- Jacob Sands, MD
- Aaron Lisberg, MD
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Project Oncology®
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
- Jacob Sands, MD
- Aaron Lisberg, MD
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Project Oncology®
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
- Jacob Sands, MD
- Alex Spira, MD, PhD, FACP
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
MinuteCE®
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
0.75 program credits
- Tanya Dorff, MD
- Rana McKay, MD
0.75 program credits
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
MinuteCE®
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
0.75 program credits
- Rana McKay, MD
0.75 program credits
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
MinuteCE®
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
1.00 program credit
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
1.00 program credit
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Project Oncology®
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
- Constance Lehman, MD, PhD
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Susana Campos, MD, MPH
1.00 program credit
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
MinuteCE®
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
0.75 program credits
- Rana McKay, MD
0.75 program credits